Argen-X

Beleggen, aandelen kopen in België, informatie, koersen en analyses

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 3998
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7393
Contacteer:

Re: Argen-X

Bericht door piddybull »

Uitbreiding met Halozyme :

https://www.halozyme.com/enhanze/pipeline/default.aspx




Under the newly announced expansion, argenx gained the ability to access Halozyme’s ENHANZE® drug delivery technology for three additional exclusive targets upon nomination bringing the total to six potential targets under the collaboration. To date, two targets have been nominated including the human neonatal Fc receptor FcRn and complement component C2.

ENHANZE® has demonstrated across five FDA-approved products the ability to remove traditional limitations on the volume of biologics that can be delivered subcutaneously, potentially shortening drug administration time, reducing healthcare practitioner time, and offering additional flexibility and convenience for patients.

Deze illustratie geeft de huidige drie aan !

Schermafbeelding 2020-10-06 om 14.53.01.png
Je hebt niet voldoende permissies om de bijlagen van dit bericht te bekijken.
Vilas liked last!
Argenx : out in anticipation

The Argonauts were able to achieve the unthinkable.







Volg Beursig.com op Twitter en Facebook


Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 3998
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7393
Contacteer:

Re: Argen-X

Bericht door piddybull »

Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE(R) Technology

SAN DIEGO, Oct. 6, 2020 -- (Healthcare Sales & Marketing Network) --

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Halozyme and argenx are expanding their existing global collaboration and license agreement that was signed in February 2019.


Under the newly announced expansion, argenx gained the ability to exclusively access Halozyme's ENHANZE® drug delivery technology for three additional targets upon nomination for a total of up to six targets under the existing and newly expanded collaboration. To date, argenx has nominated two targets including the human neonatal Fc receptor FcRn and complement component C2.

"We are pleased to be expanding the scope of our collaboration with Halozyme and to continue our productive relationship. We recognize that patients have different preferences and we want to secure our ability to offer subcutaneous delivery of our current and future candidates to reach as many patients as possible. We already have exclusive access to ENHANZE® for our FcRn antagonist efgartigimod, which is in late stage development for multiple severe autoimmune diseases, and additionally have nominated our complement inhibitor targeting C2," said Keith Woods, Chief Operating Officer of argenx.

"We are delighted that argenx has agreed to expand our global collaboration and license agreement to include up to six targets," said Dr. Helen Torley, president and chief executive officer. "argenx has made rapid progress in the clinic with efgartigimod utilizing ENHANZE® since signing the original agreement, moving to a Phase 2 study initiation for an indication being developed only as SC, within just fourteen months. argenx is also working to bring SC efgartigimod to patients suffering from myasthenia gravis following the successful ADAPT trial results."
Gillepils liked last!
Argenx : out in anticipation

The Argonauts were able to achieve the unthinkable.


Gebruikersavatar
Lama Daila
Forum elite
Forum elite
Berichten: 2197
Lid geworden op: 20 jul 2017 10:53
waarderingen: 4153
Contacteer:

Re: Argen-X

Bericht door Lama Daila »

https://twitter.com/quantumup1/status/1 ... 59297?s=21

BofA raises PT on $ARGX $298 from $265, keeps a Buy rating
•Full data strengthens our view in MG; Reiterate Buy
•Efgar’ showed rapid clinical benefits and effects on IgG/Ab
•BLA filing for MG on track by YE
80732167-B2E1-400A-818C-20EDEFE41011.png
Je hebt niet voldoende permissies om de bijlagen van dit bericht te bekijken.
brecht123 liked last!
https://twitter.com/lama_daila

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 3998
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7393
Contacteer:

Re: Argen-X

Bericht door piddybull »

Belgium is ‘European biotech leader’ for 3rd year in a row

For the third consecutive year, Belgium – of which Flanders is the northern region – can call itself “the European biotech leader”. Belgian companies account for just under a quarter (24%) of the total stock market value of all public biotech companies in Europe. Despite the COVID-19 crisis, the value of Belgian biotech companies has risen by no less than 56% in the past year, from EUR 27 billion to EUR 42 billion. These figures and trends were shared by KBC Securities at the ‘State of the Union’ organized by Flanders’ biotech strategic research center VIB and sector federation flanders.bio.


Topping the EU scoreboard
Foreign investors, companies and highly skilled employees continue to find their way to Belgium, thanks to its renowned life sciences and biotech ecosystem. Representing an impressive 24% of the total European market value, Belgium may be relatively small in size but it is well ahead of other European countries such as Denmark (21%), Germany (18%) and Spain (9%) when it comes to biotech business success.

Promising results, skyrocketing market values
Just like in previous years, Belgium’s biotech success in Europe over the past year was largely due to major players such as UCB, Argenx and Galapagos. These allowed the stock market value to rise sharply with the development of promising medicines. For example, Argenx raised over EUR 780 million, driven by the positive phase 3 clinical results of one of its antibody-based treatments for a rare autoimmune disease. This was the largest capital increase ever for a publicly traded European biotech firm.

However, smaller Belgian biotech companies – totaling a market value of under EUR 1 billion – also upped their games. As such, they saw their joint market value rise from EUR 2.2 billion to 2.6 billion in the past year, claiming 4th place in Europe. Among these smaller biotech players, the growth in Belgium’s market share can be attributed mainly to Iteos and Hyloris. Other important players include Bone Therapeutics, MDX Health, Biocartis and Mithra. Furthermore, the average market value of smaller Belgian companies has increased from EUR 171 million to EUR 259 million, putting Belgium in 2nd place in Europe.

Biotech Walhalla

“Belgium remains Europe’s biotech Valhalla,” explains Nathalie Van Den Haute, head of Equity Capital Markets within the corporate finance team of KBC Securities. “The biotech sector, like many other industries, experienced a sharp downturn in March 2020 due to the COVID-19 crisis. However, life sciences companies have done very well in recent months. Investors see the sector as a safe haven. Not only are the valuations of biotech companies less driven by short-term turnover fluctuations, but the crisis also showcased the importance of the sector very clearly. It’s therefore no surprise that biopharma indexes outperformed general indexes such as Bel20 and S&P 500. We expect 2020 to be a record year for Belgian fundraising.”

In fact, there has been a positive dynamic in Belgium and Flanders as a region for some time now when it comes to the growth of public biotech firms and the founding of new life sciences start-ups. Over the last 5 years, over 60 local start-ups came into existence. “In spite of COVID-19, the first half of 2020 has been very strong in terms of capital rounds as well,” confirms Kenneth Wils of PMV, Flanders’ investment fund.

During VIB and flanders.bio’s ‘State of the Union' event, which announces new biotech developments while analyzing Belgium’s and Flanders’ position within the European landscape, some new companies were given the chance to introduce themselves. This year, the opportunity went to six biotech companies that have recently set up locations in Flanders to benefit from the region’s successful track record in life sciences: Asylia Diagnostics, Augustine Therapeutics, Montis, MRM Health, AgomAb Therapeutics and ExeVir, the recent VIB spin-off working on a COVID-19 treatment.

Invaluable assets

“More and more of our companies are seen as world leaders in their fields – and we should be very proud of that,” says Dirk Reyn, chairman of the board of directors of life sciences sector federation flanders.bio. “In addition, foreign life sciences companies are increasingly interested in establishing themselves in our region, and we are also seeing more and more large foreign companies deciding to invest here. Our ‘Biotech Valley’ remains unique due to the high concentration of critical players in a relatively small area, ranging from biotech firms to large pharma companies and digital health experts. All of this is driven by knowledge institutions such as imec and VIB as well as by the growth of AI in Flanders.”

“Other important elements are the attractive local environment for testing new products and the presence of a highly skilled workforce alongside experienced biotech investors,” Reyn adds. “And let’s not forget our central location in Europe and our region’s long-standing experience in the life sciences industry, as well as the high availability of financial and political support from the government.”

Bron : Invest in Flanders
Terugnajaren liked last!
Argenx : out in anticipation

The Argonauts were able to achieve the unthinkable.

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 3998
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7393
Contacteer:

Re: Argen-X

Bericht door piddybull »

https://transcriptdaily.com/2020/10/07/ ... 71-00.html

Opnieuw een kleine koersdoelverhoging!

Schermafbeelding 2020-10-07 om 14.06.43.png
Je hebt niet voldoende permissies om de bijlagen van dit bericht te bekijken.
ancaoli liked last!
Argenx : out in anticipation

The Argonauts were able to achieve the unthinkable.

Gebruikersavatar
piddybull
Premiummember
Premiummember
Berichten: 3998
Lid geworden op: 21 jan 2013 22:45
Locatie: Aardbol afslag W.VL
waarderingen: 7393
Contacteer:

Re: Argen-X

Bericht door piddybull »

Op weg voor de € 250 !
Schermafbeelding 2020-10-07 om 23.59.34.png
Je hebt niet voldoende permissies om de bijlagen van dit bericht te bekijken.
Argenx : out in anticipation

The Argonauts were able to achieve the unthinkable.

Stephan
Forum actieveling
Forum actieveling
Berichten: 450
Lid geworden op: 06 aug 2014 08:50
waarderingen: 102
Contacteer:

Re: Argen-X

Bericht door Stephan »

piddybull schreef:
08 okt 2020 00:02
Op weg voor de € 250 !

Schermafbeelding 2020-10-07 om 23.59.34.png
Bijna old time high, hopelijk wordt het niet zoals Galapagos ?! Toch helft verkocht twee weken terug, sindsdien ………!

Gebruikersavatar
zwartkater
Forum actieveling
Forum actieveling
Berichten: 881
Lid geworden op: 07 apr 2014 08:26
waarderingen: 416
Contacteer:

Re: Argen-X

Bericht door zwartkater »

Nieuw ath 235.4 €

Gebruikersavatar
Lama Daila
Forum elite
Forum elite
Berichten: 2197
Lid geworden op: 20 jul 2017 10:53
waarderingen: 4153
Contacteer:

Re: Argen-X

Bericht door Lama Daila »

zwartkater schreef:
08 okt 2020 09:21
Nieuw ath 235.4 €
Volgens mij staat die nog op 239,6 EUR van deze zomer
https://twitter.com/lama_daila


Deelnemen aan het forum + meer functies?

Deel kennis en vragen met duizenden beleggers,
minder advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!



Plaats reactie